Figures & data
![Figure 1. Change in mean systolic blood pressure (SBP) during the first year of blinded treatment in the LIFE study (n = 9192). Error bars represent standard error of the mean. LIFE, Losartan Intervention For Endpoint reduction.](/cms/asset/6320a3ff-b448-4ee3-8b98-c9808a03d9c2/iblo_a_946787_f0001_b.gif)
![Figure 2. Number of patients per country with systolic blood pressure > 140 mmHg and remaining on the initial dose (50 mg) of test drug (not uptitrated by investigator) from September 2000 to April 2001 in the LIFE study. LIFE, Losartan Intervention For Endpoint reduction.](/cms/asset/a0b02710-3cf2-4f86-b3a9-efbd1d12f328/iblo_a_946787_f0002_b.gif)
Table I. Number of patients per country with systolic blood pressure > 140 mmHg and remaining on the initial dose (50 mg) of test drug (not uptitrated by investigator) from September 2000 to April 2001 in the LIFE study.
![Figure 3. Mean systolic blood pressure (SBP) during the first 30 months of the VALUE trial in patients with untreated or treated hypertension at baseline. Error bars represent standard deviation. VALUE, Valsartan Antihypertensive Long-term Use Evaluation.](/cms/asset/9e0eb557-d1de-47fb-b130-e822257c39aa/iblo_a_946787_f0003_b.gif)
![Figure 4. Percentage of patients reaching systolic and diastolic blood pressure (SBP and DBP) targets during the first 30 months of the VALUE trial, and percentages of patients receiving the lowest and highest doses of study drug after 6 and 30 months. VALUE, Valsartan Antihypertensive Long-term Use Evaluation.](/cms/asset/a36fad60-d143-4c7e-8d4b-61030674d60b/iblo_a_946787_f0004_b.gif)
![Figure 5. Proportion of patients not reaching target diastolic blood pressure (DBP), according to dose titration step, in 4 years of the ASCOT study. ASCOT, Anglo-Scandinavian Cardiac Outcomes Trial.](/cms/asset/e56c8bc2-f8e4-4d7d-9238-726ff7b443ef/iblo_a_946787_f0005_b.gif)
![Figure 6. Number of randomized patients and blood pressure control rate (< 140/90 mmHg) over time in the ACCOMPLISH trial (data as of October 2006). ACCOMPLISH, Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension.](/cms/asset/53d76b74-e5bb-4263-ade8-39f08e3460d5/iblo_a_946787_f0006_b.gif)
![Figure 7. Proportions of patients at each dose level (DL) according to blood pressure (BP) control defined as BP < 140/90 mmHg or BP < 130/80 mmHg at month 6 in the ACCOMPLISH trial (data as of October 2005). ACCOMPLISH, Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension.](/cms/asset/3fb6ba8a-ee9b-4ddd-8c3c-4eac5cb31bd6/iblo_a_946787_f0007_b.gif)
Register now or learn more
Free access
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.